UGN-102, a Direct-to-Bladder Therapy, Improves Bladder Cance

Findings from the phase 3 ATLAS and ENVISION trials reveal a non-surgical way to possibly benefit patients with low-grade, intermediate- risk non-muscle invasive bladder cancer.

Related Keywords

New Jersey , United States , Urogen Pharma , Sandip Prasad , Liz Barrett , Drug Administration , Genitourinary Surgical Oncology , Morristown Medical , Atlantic Health System , New Drug Application ,